<p>安聯集團在最近向證券交易委員會提交的 13F 文件中表示，在第二季度減少了對百時美施貴寶公司的持股，減幅為 5.5%。該基金在季度內出售了 5,501 股後，持有 94,623 股該生物製藥公司的股票。安聯集團在百時美施貴寶的持股在最近一個季度末的價值為 4,380,000 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>其他幾家機構投資者最近也調整了對該股票的持股。Trifecta Capital Advisors LLC 在第二季度購買了百時美施貴寶的新頭寸，價值 25,000 美元。REAP Financial Group LLC 在第二季度將其在百時美施貴寶的持股增加了 202.8%。REAP Financial Group LLC 現在擁有 639 股該生物製藥公司的股票，價值 30,000 美元，此前在上個季度又收購了 428 股。Accent Capital Management LLC 在第一季度以 33,000 美元的估值購買了百時美施貴寶的新頭寸。CBIZ Investment Advisory Services LLC 在第一季度將其在百時美施貴寶的持股增加了 66.0%。CBIZ Investment Advisory Services LLC 現在擁有 581 股該生物製藥公司的股票，價值 35,000 美元，此前在上個季度又收購了 231 股。最後，GKV Capital Management Co. Inc.在第一季度以約 36,000 美元的估值購買了百時美施貴寶的新股份。目前 76.41% 的股票由機構投資者持有。</p>
<h2>百時美施貴寶的內部交易</h2>
<p>在其他百時美施貴寶的新聞中，執行副總裁 David V. Elkins 於 9 月 2 日星期二出售了 56,000 股公司的股票。股票以平均價格 47.33 美元出售，總價值為 2,650,480.00 美元。交易完成後，該執行副總裁直接持有 167,379 股公司股票，估值約為 7,922,048.07 美元。這代表其持股減少了 25.07%。該出售在向證券交易委員會提交的文件中披露，可以通過 SEC 網站訪問。內部人士持有公司股票的 0.09%。</p>
<h2>百時美施貴寶股票下跌 0.9%</h2>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>週五，紐約證券交易所 BMY 的開盤價為 48.64 美元。百時美施貴寶公司的 1 年最低價為 42.52 美元，1 年最高價為 63.33 美元。該股票的市值為 990.2 億美元，市盈率為 19.61，市盈增長比率為 2.23，貝塔係數為 0.33。公司的債務與股本比率為 2.54，流動比率為 1.21，速動比率為 1.11。該公司的 50 日移動平均線為 45.35 美元，200 日移動平均線為 46.71 美元。</p>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近於 10 月 30 日星期四發佈了季度財報。這家生物製藥公司報告季度每股收益為 1.63 美元，超出分析師一致預期的 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司在本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。在去年同期，該公司發佈的每股收益為 1.80 美元。百時美施貴寶的季度收入較去年同期增長了 2.8%。百時美施貴寶已將其 2025 財年的指導目標設定為每股收益 6.400-6.600 美元。賣方分析師預測百時美施貴寶公司今年的每股收益將達到 6.74 美元。</p>
<h2>百時美施貴寶分紅公告</h2>
<ul>
<li>百時美施貴寶的疲軟指引可能創造機會</li>
</ul>
<p>該公司最近還披露了季度分紅，已於 11 月 3 日星期一支付。10 月 3 日星期五的股東獲得每股 0.62 美元的分紅。這相當於年化分紅 2.48 美元，收益率為 5.1%。該分紅的除息日為 10 月 3 日星期五。百時美施貴寶的派息比率目前為 83.78%。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商最近對 BMY 發表了評論。Sanford C. Bernstein 在 11 月 3 日星期一的研究報告中重申了對百時美施貴寶股票的 “市場表現” 評級。Weiss Ratings 在 10 月 14 日星期二的研究報告中重申了對百時美施貴寶股票的 “持有（c-）” 評級。摩根士丹利在 7 月 31 日星期四的研究報告中重新發布了對百時美施貴寶股票的 “持有” 評級。大和美國在 8 月 5 日星期二將百時美施貴寶的評級從 “強力買入” 下調至 “持有”。最後，大和資本市場在 8 月 5 日星期二將百時美施貴寶的評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。四位研究分析師對該股票給予了買入評級，十五位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，百時美施貴寶的平均評級為 “持有”，平均目標價為 54.58 美元。</p>
<p><strong>閲讀我們對 BMY 的最新分析</strong></p>
<h2>關於百時美施貴寶</h2>
<p>（免費報告）</p>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性房顫患者中風/全身性栓塞的風險，以及用於治療深靜脈血栓/肺栓塞；Opdivo 用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>儘管第三季度業績出色，dLocal 股價仍下跌——投資者錯過了什麼</li>
<li>市盈率計算：如何評估股票</li>
<li>Ondas Holdings 在無人機需求激增中發出反彈信號</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>在艾格的魔力下，迪士尼 2026 年的前景變得更加光明</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

安聯集團(ADR)

<p>安聯集團 (ADR) 在第二季度減少了對百時美施貴寶的持股 5.5%，目前持有 94,623 股，價值 438 萬美元。其他機構投資者也調整了他們的持倉。百時美施貴寶的股票開盤價為 48.64 美元，市值為 990.2 億美元。該公司報告第三季度每股收益為 1.63 美元，超出預期，並宣佈季度股息為每股 0.62 美元。分析師設定了新的價格目標，評級來自不同券商的反饋不一</p>

<p>Allianz SE lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,623 shares of the biopharmaceutical company's stock after selling 5,501 shares during the quarter. Allianz SE's holdings in Bristol Myers Squibb were worth $4,380,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>安聯集團在最近向證券交易委員會提交的 13F 文件中表示，在第二季度減少了對百時美施貴寶公司的持股，減幅為 5.5%。該基金在季度內出售了 5,501 股後，持有 94,623 股該生物製藥公司的股票。安聯集團在百時美施貴寶的持股在最近一個季度末的價值為 4,380,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>Several other institutional investors also recently modified their holdings of the stock. Trifecta Capital Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. REAP Financial Group LLC grew its position in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 428 shares in the last quarter. Accent Capital Management LLC bought a new position in Bristol Myers Squibb in the first quarter valued at $33,000. CBIZ Investment Advisory Services LLC increased its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in Bristol Myers Squibb during the first quarter valued at about $36,000. 76.41% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也調整了對該股票的持股。Trifecta Capital Advisors LLC 在第二季度購買了百時美施貴寶的新頭寸，價值 25,000 美元。REAP Financial Group LLC 在第二季度將其在百時美施貴寶的持股增加了 202.8%。REAP Financial Group LLC 現在擁有 639 股該生物製藥公司的股票，價值 30,000 美元，此前在上個季度又收購了 428 股。Accent Capital Management LLC 在第一季度以 33,000 美元的估值購買了百時美施貴寶的新頭寸。CBIZ Investment Advisory Services LLC 在第一季度將其在百時美施貴寶的持股增加了 66.0%。CBIZ Investment Advisory Services LLC 現在擁有 581 股該生物製藥公司的股票，價值 35,000 美元，此前在上個季度又收購了 231 股。最後，GKV Capital Management Co. Inc.在第一季度以約 36,000 美元的估值購買了百時美施貴寶的新股份。目前 76.41% 的股票由機構投資者持有。</p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百時美施貴寶的內部交易</h2>
</div><p>In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他百時美施貴寶的新聞中，執行副總裁 David V. Elkins 於 9 月 2 日星期二出售了 56,000 股公司的股票。股票以平均價格 47.33 美元出售，總價值為 2,650,480.00 美元。交易完成後，該執行副總裁直接持有 167,379 股公司股票，估值約為 7,922,048.07 美元。這代表其持股減少了 25.07%。該出售在向證券交易委員會提交的文件中披露，可以通過 SEC 網站訪問。內部人士持有公司股票的 0.09%。</p>
</div><h2>Bristol Myers Squibb Stock Down 0.9%</h2>
<div class="lb-trans"><h2>百時美施貴寶股票下跌 0.9%</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>NYSE BMY opened at $48.64 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market capitalization of $99.02 billion, a PE ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The business's 50-day moving average is $45.35 and its 200 day moving average is $46.71.</p>
<div class="lb-trans"><p>週五，紐約證券交易所 BMY 的開盤價為 48.64 美元。百時美施貴寶公司的 1 年最低價為 42.52 美元，1 年最高價為 63.33 美元。該股票的市值為 990.2 億美元，市盈率為 19.61，市盈增長比率為 2.23，貝塔係數為 0.33。公司的債務與股本比率為 2.54，流動比率為 1.21，速動比率為 1.11。該公司的 50 日移動平均線為 45.35 美元，200 日移動平均線為 46.71 美元。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb's quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近於 10 月 30 日星期四發佈了季度財報。這家生物製藥公司報告季度每股收益為 1.63 美元，超出分析師一致預期的 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司在本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。在去年同期，該公司發佈的每股收益為 1.80 美元。百時美施貴寶的季度收入較去年同期增長了 2.8%。百時美施貴寶已將其 2025 財年的指導目標設定為每股收益 6.400-6.600 美元。賣方分析師預測百時美施貴寶公司今年的每股收益將達到 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百時美施貴寶分紅公告</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的疲軟指引可能創造機會</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb's payout ratio is presently 83.78%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，已於 11 月 3 日星期一支付。10 月 3 日星期五的股東獲得每股 0.62 美元的分紅。這相當於年化分紅 2.48 美元，收益率為 5.1%。該分紅的除息日為 10 月 3 日星期五。百時美施貴寶的派息比率目前為 83.78%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages have recently commented on BMY. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley reissued a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America lowered shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, August 5th. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Four research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of &#34;Hold&#34; and an average target price of $54.58.</p>
<div class="lb-trans"><p>幾家券商最近對 BMY 發表了評論。Sanford C. Bernstein 在 11 月 3 日星期一的研究報告中重申了對百時美施貴寶股票的 “市場表現” 評級。Weiss Ratings 在 10 月 14 日星期二的研究報告中重申了對百時美施貴寶股票的 “持有（c-）” 評級。摩根士丹利在 7 月 31 日星期四的研究報告中重新發布了對百時美施貴寶股票的 “持有” 評級。大和美國在 8 月 5 日星期二將百時美施貴寶的評級從 “強力買入” 下調至 “持有”。最後，大和資本市場在 8 月 5 日星期二將百時美施貴寶的評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。四位研究分析師對該股票給予了買入評級，十五位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，百時美施貴寶的平均評級為 “持有”，平均目標價為 54.58 美元。</p>
</div><p><strong>Read Our Latest Analysis on BMY</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 BMY 的最新分析</strong></p>
</div><h2>About Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>關於百時美施貴寶</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性房顫患者中風/全身性栓塞的風險，以及用於治療深靜脈血栓/肺栓塞；Opdivo 用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Ondas Holdings Signals a Rebound as Drone Demand Soars</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Disney’s 2026 Outlook Brightens Under Iger's Magic Touch</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>儘管第三季度業績出色，dLocal 股價仍下跌——投資者錯過了什麼</li>
<li>市盈率計算：如何評估股票</li>
<li>Ondas Holdings 在無人機需求激增中發出反彈信號</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>在艾格的魔力下，迪士尼 2026 年的前景變得更加光明</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

安聯集團 (ADR) 減少了在百時美施貴寶公司 $BMY 的持倉